Galectin-3 Inhibitor Market, Global Outlook and Forecast 2022-2028

June 2022 | 61 pages | ID: G6B6A6914B80EN
Market Monitor Global

Abstracts

This report contains market size and forecasts of Galectin-3 Inhibitor in Global, including the following market information:

Global Galectin-3 Inhibitor Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Galectin-3 Inhibitor market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Natural Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Galectin-3 Inhibitor include GlycoMimetics (US), Galectin Therapeutics Inc (US), G3 Pharmaceuticals (India), iTeos (US), MandalMed, Inc (US), Angion (US), Novartis AG (Switzerland), Galecto Biotech (Denmark) and Pfizer Inc. (US) and etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Galectin-3 Inhibitor companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Galectin-3 Inhibitor Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Galectin-3 Inhibitor Market Segment Percentages, by Type, 2021 (%)

• Natural
• Synthetic

Global Galectin-3 Inhibitor Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Galectin-3 Inhibitor Market Segment Percentages, by Application, 2021 (%)

• Diabetes
• Heart Failure
• Asthma
• Rheumatoid Arthritis
• Other

Global Galectin-3 Inhibitor Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Galectin-3 Inhibitor Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Galectin-3 Inhibitor revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Galectin-3 Inhibitor revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• GlycoMimetics (US)
• Galectin Therapeutics Inc (US)
• G3 Pharmaceuticals (India)
• iTeos (US)
• MandalMed, Inc (US)
• Angion (US)
• Novartis AG (Switzerland)
• Galecto Biotech (Denmark)
• Pfizer Inc. (US)
• Lilly (US)

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Galectin-3 Inhibitor Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Galectin-3 Inhibitor Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL GALECTIN-3 INHIBITOR OVERALL MARKET SIZE

2.1 Global Galectin-3 Inhibitor Market Size: 2021 VS 2028
2.2 Global Galectin-3 Inhibitor Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Galectin-3 Inhibitor Players in Global Market
3.2 Top Global Galectin-3 Inhibitor Companies Ranked by Revenue
3.3 Global Galectin-3 Inhibitor Revenue by Companies
3.4 Top 3 and Top 5 Galectin-3 Inhibitor Companies in Global Market, by Revenue in 2021
3.5 Global Companies Galectin-3 Inhibitor Product Type
3.6 Tier 1, Tier 2 and Tier 3 Galectin-3 Inhibitor Players in Global Market
  3.6.1 List of Global Tier 1 Galectin-3 Inhibitor Companies
  3.6.2 List of Global Tier 2 and Tier 3 Galectin-3 Inhibitor Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Galectin-3 Inhibitor Market Size Markets, 2021 & 2028
  4.1.2 Natural
  4.1.3 Synthetic
4.2 By Type - Global Galectin-3 Inhibitor Revenue & Forecasts
  4.2.1 By Type - Global Galectin-3 Inhibitor Revenue, 2017-2022
  4.2.2 By Type - Global Galectin-3 Inhibitor Revenue, 2023-2028
  4.2.3 By Type - Global Galectin-3 Inhibitor Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Galectin-3 Inhibitor Market Size, 2021 & 2028
  5.1.2 Diabetes
  5.1.3 Heart Failure
  5.1.4 Asthma
  5.1.5 Rheumatoid Arthritis
  5.1.6 Other
5.2 By Application - Global Galectin-3 Inhibitor Revenue & Forecasts
  5.2.1 By Application - Global Galectin-3 Inhibitor Revenue, 2017-2022
  5.2.2 By Application - Global Galectin-3 Inhibitor Revenue, 2023-2028
  5.2.3 By Application - Global Galectin-3 Inhibitor Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Galectin-3 Inhibitor Market Size, 2021 & 2028
6.2 By Region - Global Galectin-3 Inhibitor Revenue & Forecasts
  6.2.1 By Region - Global Galectin-3 Inhibitor Revenue, 2017-2022
  6.2.2 By Region - Global Galectin-3 Inhibitor Revenue, 2023-2028
  6.2.3 By Region - Global Galectin-3 Inhibitor Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Galectin-3 Inhibitor Revenue, 2017-2028
  6.3.2 US Galectin-3 Inhibitor Market Size, 2017-2028
  6.3.3 Canada Galectin-3 Inhibitor Market Size, 2017-2028
  6.3.4 Mexico Galectin-3 Inhibitor Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Galectin-3 Inhibitor Revenue, 2017-2028
  6.4.2 Germany Galectin-3 Inhibitor Market Size, 2017-2028
  6.4.3 France Galectin-3 Inhibitor Market Size, 2017-2028
  6.4.4 U.K. Galectin-3 Inhibitor Market Size, 2017-2028
  6.4.5 Italy Galectin-3 Inhibitor Market Size, 2017-2028
  6.4.6 Russia Galectin-3 Inhibitor Market Size, 2017-2028
  6.4.7 Nordic Countries Galectin-3 Inhibitor Market Size, 2017-2028
  6.4.8 Benelux Galectin-3 Inhibitor Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Galectin-3 Inhibitor Revenue, 2017-2028
  6.5.2 China Galectin-3 Inhibitor Market Size, 2017-2028
  6.5.3 Japan Galectin-3 Inhibitor Market Size, 2017-2028
  6.5.4 South Korea Galectin-3 Inhibitor Market Size, 2017-2028
  6.5.5 Southeast Asia Galectin-3 Inhibitor Market Size, 2017-2028
  6.5.6 India Galectin-3 Inhibitor Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Galectin-3 Inhibitor Revenue, 2017-2028
  6.6.2 Brazil Galectin-3 Inhibitor Market Size, 2017-2028
  6.6.3 Argentina Galectin-3 Inhibitor Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Galectin-3 Inhibitor Revenue, 2017-2028
  6.7.2 Turkey Galectin-3 Inhibitor Market Size, 2017-2028
  6.7.3 Israel Galectin-3 Inhibitor Market Size, 2017-2028
  6.7.4 Saudi Arabia Galectin-3 Inhibitor Market Size, 2017-2028
  6.7.5 UAE Galectin-3 Inhibitor Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 GlycoMimetics (US)
  7.1.1 GlycoMimetics (US) Corporate Summary
  7.1.2 GlycoMimetics (US) Business Overview
  7.1.3 GlycoMimetics (US) Galectin-3 Inhibitor Major Product Offerings
  7.1.4 GlycoMimetics (US) Galectin-3 Inhibitor Revenue in Global Market (2017-2022)
  7.1.5 GlycoMimetics (US) Key News
7.2 Galectin Therapeutics Inc (US)
  7.2.1 Galectin Therapeutics Inc (US) Corporate Summary
  7.2.2 Galectin Therapeutics Inc (US) Business Overview
  7.2.3 Galectin Therapeutics Inc (US) Galectin-3 Inhibitor Major Product Offerings
  7.2.4 Galectin Therapeutics Inc (US) Galectin-3 Inhibitor Revenue in Global Market (2017-2022)
  7.2.5 Galectin Therapeutics Inc (US) Key News
7.3 G3 Pharmaceuticals (India)
  7.3.1 G3 Pharmaceuticals (India) Corporate Summary
  7.3.2 G3 Pharmaceuticals (India) Business Overview
  7.3.3 G3 Pharmaceuticals (India) Galectin-3 Inhibitor Major Product Offerings
  7.3.4 G3 Pharmaceuticals (India) Galectin-3 Inhibitor Revenue in Global Market (2017-2022)
  7.3.5 G3 Pharmaceuticals (India) Key News
7.4 iTeos (US)
  7.4.1 iTeos (US) Corporate Summary
  7.4.2 iTeos (US) Business Overview
  7.4.3 iTeos (US) Galectin-3 Inhibitor Major Product Offerings
  7.4.4 iTeos (US) Galectin-3 Inhibitor Revenue in Global Market (2017-2022)
  7.4.5 iTeos (US) Key News
7.5 MandalMed, Inc (US)
  7.5.1 MandalMed, Inc (US) Corporate Summary
  7.5.2 MandalMed, Inc (US) Business Overview
  7.5.3 MandalMed, Inc (US) Galectin-3 Inhibitor Major Product Offerings
  7.5.4 MandalMed, Inc (US) Galectin-3 Inhibitor Revenue in Global Market (2017-2022)
  7.5.5 MandalMed, Inc (US) Key News
7.6 Angion (US)
  7.6.1 Angion (US) Corporate Summary
  7.6.2 Angion (US) Business Overview
  7.6.3 Angion (US) Galectin-3 Inhibitor Major Product Offerings
  7.6.4 Angion (US) Galectin-3 Inhibitor Revenue in Global Market (2017-2022)
  7.6.5 Angion (US) Key News
7.7 Novartis AG (Switzerland)
  7.7.1 Novartis AG (Switzerland) Corporate Summary
  7.7.2 Novartis AG (Switzerland) Business Overview
  7.7.3 Novartis AG (Switzerland) Galectin-3 Inhibitor Major Product Offerings
  7.7.4 Novartis AG (Switzerland) Galectin-3 Inhibitor Revenue in Global Market (2017-2022)
  7.7.5 Novartis AG (Switzerland) Key News
7.8 Galecto Biotech (Denmark)
  7.8.1 Galecto Biotech (Denmark) Corporate Summary
  7.8.2 Galecto Biotech (Denmark) Business Overview
  7.8.3 Galecto Biotech (Denmark) Galectin-3 Inhibitor Major Product Offerings
  7.8.4 Galecto Biotech (Denmark) Galectin-3 Inhibitor Revenue in Global Market (2017-2022)
  7.8.5 Galecto Biotech (Denmark) Key News
7.9 Pfizer Inc. (US)
  7.9.1 Pfizer Inc. (US) Corporate Summary
  7.9.2 Pfizer Inc. (US) Business Overview
  7.9.3 Pfizer Inc. (US) Galectin-3 Inhibitor Major Product Offerings
  7.9.4 Pfizer Inc. (US) Galectin-3 Inhibitor Revenue in Global Market (2017-2022)
  7.9.5 Pfizer Inc. (US) Key News
7.10 Lilly (US)
  7.10.1 Lilly (US) Corporate Summary
  7.10.2 Lilly (US) Business Overview
  7.10.3 Lilly (US) Galectin-3 Inhibitor Major Product Offerings
  7.10.4 Lilly (US) Galectin-3 Inhibitor Revenue in Global Market (2017-2022)
  7.10.5 Lilly (US) Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Galectin-3 Inhibitor Market Opportunities & Trends in Global Market
Table 2. Galectin-3 Inhibitor Market Drivers in Global Market
Table 3. Galectin-3 Inhibitor Market Restraints in Global Market
Table 4. Key Players of Galectin-3 Inhibitor in Global Market
Table 5. Top Galectin-3 Inhibitor Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Galectin-3 Inhibitor Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Galectin-3 Inhibitor Revenue Share by Companies, 2017-2022
Table 8. Global Companies Galectin-3 Inhibitor Product Type
Table 9. List of Global Tier 1 Galectin-3 Inhibitor Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Galectin-3 Inhibitor Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Galectin-3 Inhibitor Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Galectin-3 Inhibitor Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Galectin-3 Inhibitor Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Galectin-3 Inhibitor Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Galectin-3 Inhibitor Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Galectin-3 Inhibitor Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Galectin-3 Inhibitor Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Galectin-3 Inhibitor Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Galectin-3 Inhibitor Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Galectin-3 Inhibitor Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Galectin-3 Inhibitor Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Galectin-3 Inhibitor Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Galectin-3 Inhibitor Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Galectin-3 Inhibitor Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Galectin-3 Inhibitor Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Galectin-3 Inhibitor Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Galectin-3 Inhibitor Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Galectin-3 Inhibitor Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Galectin-3 Inhibitor Revenue, (US$, Mn), 2023-2028
Table 30. GlycoMimetics (US) Corporate Summary
Table 31. GlycoMimetics (US) Galectin-3 Inhibitor Product Offerings
Table 32. GlycoMimetics (US) Galectin-3 Inhibitor Revenue (US$, Mn), (2017-2022)
Table 33. Galectin Therapeutics Inc (US) Corporate Summary
Table 34. Galectin Therapeutics Inc (US) Galectin-3 Inhibitor Product Offerings
Table 35. Galectin Therapeutics Inc (US) Galectin-3 Inhibitor Revenue (US$, Mn), (2017-2022)
Table 36. G3 Pharmaceuticals (India) Corporate Summary
Table 37. G3 Pharmaceuticals (India) Galectin-3 Inhibitor Product Offerings
Table 38. G3 Pharmaceuticals (India) Galectin-3 Inhibitor Revenue (US$, Mn), (2017-2022)
Table 39. iTeos (US) Corporate Summary
Table 40. iTeos (US) Galectin-3 Inhibitor Product Offerings
Table 41. iTeos (US) Galectin-3 Inhibitor Revenue (US$, Mn), (2017-2022)
Table 42. MandalMed, Inc (US) Corporate Summary
Table 43. MandalMed, Inc (US) Galectin-3 Inhibitor Product Offerings
Table 44. MandalMed, Inc (US) Galectin-3 Inhibitor Revenue (US$, Mn), (2017-2022)
Table 45. Angion (US) Corporate Summary
Table 46. Angion (US) Galectin-3 Inhibitor Product Offerings
Table 47. Angion (US) Galectin-3 Inhibitor Revenue (US$, Mn), (2017-2022)
Table 48. Novartis AG (Switzerland) Corporate Summary
Table 49. Novartis AG (Switzerland) Galectin-3 Inhibitor Product Offerings
Table 50. Novartis AG (Switzerland) Galectin-3 Inhibitor Revenue (US$, Mn), (2017-2022)
Table 51. Galecto Biotech (Denmark) Corporate Summary
Table 52. Galecto Biotech (Denmark) Galectin-3 Inhibitor Product Offerings
Table 53. Galecto Biotech (Denmark) Galectin-3 Inhibitor Revenue (US$, Mn), (2017-2022)
Table 54. Pfizer Inc. (US) Corporate Summary
Table 55. Pfizer Inc. (US) Galectin-3 Inhibitor Product Offerings
Table 56. Pfizer Inc. (US) Galectin-3 Inhibitor Revenue (US$, Mn), (2017-2022)
Table 57. Lilly (US) Corporate Summary
Table 58. Lilly (US) Galectin-3 Inhibitor Product Offerings
Table 59. Lilly (US) Galectin-3 Inhibitor Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Galectin-3 Inhibitor Segment by Type in 2021
Figure 2. Galectin-3 Inhibitor Segment by Application in 2021
Figure 3. Global Galectin-3 Inhibitor Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Galectin-3 Inhibitor Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Galectin-3 Inhibitor Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Galectin-3 Inhibitor Revenue in 2021
Figure 8. By Type - Global Galectin-3 Inhibitor Revenue Market Share, 2017-2028
Figure 9. By Application - Global Galectin-3 Inhibitor Revenue Market Share, 2017-2028
Figure 10. By Region - Global Galectin-3 Inhibitor Revenue Market Share, 2017-2028
Figure 11. By Country - North America Galectin-3 Inhibitor Revenue Market Share, 2017-2028
Figure 12. US Galectin-3 Inhibitor Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Galectin-3 Inhibitor Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Galectin-3 Inhibitor Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Galectin-3 Inhibitor Revenue Market Share, 2017-2028
Figure 16. Germany Galectin-3 Inhibitor Revenue, (US$, Mn), 2017-2028
Figure 17. France Galectin-3 Inhibitor Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Galectin-3 Inhibitor Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Galectin-3 Inhibitor Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Galectin-3 Inhibitor Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Galectin-3 Inhibitor Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Galectin-3 Inhibitor Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Galectin-3 Inhibitor Revenue Market Share, 2017-2028
Figure 24. China Galectin-3 Inhibitor Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Galectin-3 Inhibitor Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Galectin-3 Inhibitor Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Galectin-3 Inhibitor Revenue, (US$, Mn), 2017-2028
Figure 28. India Galectin-3 Inhibitor Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Galectin-3 Inhibitor Revenue Market Share, 2017-2028
Figure 30. Brazil Galectin-3 Inhibitor Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Galectin-3 Inhibitor Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Galectin-3 Inhibitor Revenue Market Share, 2017-2028
Figure 33. Turkey Galectin-3 Inhibitor Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Galectin-3 Inhibitor Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Galectin-3 Inhibitor Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Galectin-3 Inhibitor Revenue, (US$, Mn), 2017-2028
Figure 37. GlycoMimetics (US) Galectin-3 Inhibitor Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Galectin Therapeutics Inc (US) Galectin-3 Inhibitor Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. G3 Pharmaceuticals (India) Galectin-3 Inhibitor Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. iTeos (US) Galectin-3 Inhibitor Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. MandalMed, Inc (US) Galectin-3 Inhibitor Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Angion (US) Galectin-3 Inhibitor Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Novartis AG (Switzerland) Galectin-3 Inhibitor Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Galecto Biotech (Denmark) Galectin-3 Inhibitor Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Pfizer Inc. (US) Galectin-3 Inhibitor Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. Lilly (US) Galectin-3 Inhibitor Revenue Year Over Year Growth (US$, Mn) & (2017-2022)